STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
STAT PlusOpinionAdam’s Take Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial The unexpected result is good news for patients with acute myeloid leukemia Manage alerts for this article Save this story for later Share this article By Adam FeuersteinNov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said. Advertisement In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study. STAT+ Exclusive Story Already have an account?
Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!
Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Clinical trials, FDA, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Adam's Biotech Scorecard November 12, 2026 STAT Plus: What to know about Biogen’s big lupus study readout Adam's Biotech Scorecard November 12, 2026 STAT Plus: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem Advertisement Adam's Biotech Scorecard November 5, 2026 STAT Plus: A closer look at ProMis Neurosciences and its Alzheimer’s drug Adam's Biotech Scorecard October 29, 2026 STAT Plus: Vertex kidney disease drug scrutinized for infection risk Adam's Biotech Scorecard October 15, 2026 STAT Plus: On Wall Street, there’s trouble stirring for biotech Subscriber Picks
comments(0)
5-min edit window · permanent after that